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ER stressNeurones undergo diverse forms of cell death depending on the nature and severity of the stress. These
death outcomes are now classiﬁed into various types of programmed cell death, including apoptosis,
autophagy and necrosis. Each of these pathways can run in parallel and all have mitochondria as a central
feature. Recruitment of mitochondria into cell death signalling involves either (or both) induction of speciﬁc
death responses through release of apoptogenic proteins into the cytosol, or perturbation in function leading
to loss of mitochondrial energisation and ATP synthesis. Cross-talk between these signalling pathways,
particularly downstream of mitochondria, determines the resultant pattern of cell death. The differential
recruitment of speciﬁc death pathways depends on the timing of engagement of mitochondrial signalling.
Other inﬂuences on programmed cell death pathways occur through stress of the endoplasmic reticulum and
the associated ubiquitin-proteasome system normally handling potentially neurotoxic protein aggregates.
Based upon contemporary evidence apoptosis is a relatively rare in the mature brain whereas the
contribution of programmed necrosis to various neuropathologies has been underestimated. The death
outcomes that neurones exhibit during acute or chronic injury or pathological conditions considered here
(oxidative stress, hypoxic-ischaemic injury, amyotrophic lateral sclerosis, Parkinson's and Huntington's
diseases) fall within a spectrum of the diverse death types across the apoptosis-necrosis continuum. Indeed,
dying or dead neurones may simultaneously manifest characteristics of more than one type of death
pathway. Understanding neuronal death pathways and their cross-talk not only informs the detailed
pathobiology but also suggests novel therapeutic strategies.tes, University of Melbourne,
5; fax: +61 3 9347 0446.
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ll rights reserved.© 2009 Elsevier B.V. All rights reserved.1. Overview and general principles of diverse neuronal cell death
modalities
Neurones die in a variety of ways and mitochondria play a key role
in such outcomes. This topical review explores the recent literature
underlying the nature of neuronal death and its contextualisation in
injury and disease. Particular emphasis is placed on mitochondria as
organelles that, on the one hand, provide bioenergetic sustenance to
the cell and, on the other, act as the focal point of cellular signalling
leading to various types of death outcome. Because scientiﬁc
discourse in this ﬁeld is characterized by the use of numerous
abbreviations, a list of those used here is in Table 1.
Various markers of cell death have been used to identify the
outcome of cellular injury or neurodegeneration in the nervous
system. Thus, in stroke-affected brain (similar to hypoxic-ischaemic(HI) injury) necrosis clearly occurs at the core of the injury site. There
is a penumbra surrounding this core, which is characterised by cells
with apoptotic markers such as caspase activation and nuclear DNA
fragmentation [1]. In neurodegenerative diseases such as amyo-
trophic lateral sclerosis (ALS), markers of apoptosis are observed,
together with evidence of cellular stress responses including
endoplasmic reticulum (ER) stress and markers of autophagy [2].
In these and other pathological settings,mitochondria in the affected
cells, being central to cellular homeostatic and energy-yielding
activities, play key regulatory roles in death processes. Thus, these
organelles receive signals from pro-apoptotic members of the Bcl-2
family, which are antagonised by other pro-survival (anti-apoptotic)
members of the same protein family. In situations where the pro-
apoptotic Bcl-2 family proteins predominate, outer mitochondrial
membrane permeabilisation (OMMP) results, thereby allowing redis-
tribution to the cytosol of a number of apoptogenic proteins [3–5]. These
proteins enable progression of programmed cell death (PCD), initially
deﬁned as apoptosis. However, as will be discussed later in this review,
mitochondria inﬂuence not only apoptosis (PCD-Type I) but also can
engender amore recently identiﬁed death outcome called programmed
necrosis (PCD-Type III), typiﬁed by lack of caspase involvement [6].
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mechanism for turnover of various cellular constituents, but under
some stress conditions may become part of the death program leading
to autophagic cell death (PCD-type II) [6–8].
Neurones are complex cells relative to many other cell types. They
have the characteristic morphology of a cell body, with greatly
elongated processes (axons and dendrites), with consequential
transport issues for intracellular trafﬁcking. Moreover they have a
plethora of surface ion channels, and are very susceptible to injury
(and death) through deprivation of energy or molecular ATP, or via
severe excitation by neurotransmitters producing excitotoxicity.
These events can produce elevation of intracellular andmitochondrial
Ca2+, key determinants of PCD through various mechanisms [9,10] ,
including generation of reactive oxygen species (ROS) and involve-
ment of mitochondrial permeability transition (MPT) and/or OMMPTable 1
List of abbreviations.
Abbreviations Deﬁnitions
AD Alzheimer's disease
AIF Apoptosis inducing factor
ALS Amyotrophic lateral sclerosis
ATF6 Activating transcription factor 6
BH-3 Bcl-2 Homology domain 3
BiP Immunoglobulin-binding protein
CHOP C/EBP homologous protein
CMA Chaperone-mediated autophagy
CypD Cyclophilin D
Cyt c Cytochrome c
DA Dopaminergic
Endo G Endonuclease G
ER Endoplasmic reticulum
ERAD ER-associated protein degradation
FALS Familial ALS
HD Huntington's disease
HI Hypoxia-ischemia
Htt Huntingtin
IMM Inner mitochondrial membrane
IMS Intermembrane space
IP3 Inositol-1,4,5-triphosphate
IP3R Inositol-1,4,5-triphosphate receptor
IRE1 Inositol-requiring kinase 1
JNK c-Jun N-terminal kinase
LC3 Microtubule-associated protein 1-light chain 3
MA Macroautophagy
MN Motor neurones
MP Misfolded proteins
MPP+ 1-methyl-4-phenylpyridinium
MPT Membrane permeability transition
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Nec-1 Necrostatin-1
OMM Outer mitochondrial membrane
OMMP Outer mitochondrial membrane permeabilization
PARP-1 Poly(ADP-ribose) polymerase 1
PCD Programmed cell death
PD Parkinson's disease
PDI Protein disulphide isomerase
PERK PRK-like endoplasmic reticulum kinase
PINK1 PTEN-induced kinase 1
RIP-1 Receptor interacting protein-1
RONS Reactive oxygen and nitrogen species
ROS Reactive oxygen species
SALS Sporadic ALS
S m a c /
DIABLO
Second mitochondria-derived activator of caspases/direct
inhibitor of apoptosis-binding protein with low PI
SNc Substantia nigra pars compacta
SOD1 Superoxide dismutase 1
TRAF2 TNF receptor-associated factor 2
UPR Unfolded protein response
UPRmt Mitochondrial unfolded protein response
UPS Ubiquitin-proteasome system
αSN α-Synuclein
ΔΨm Mitochondrial membrane potential
List shows abbreviations used more than once after the initial deﬁnition in the text.(see below for details). Recent evidence in non-neuronal cells
indicates elevated Ca2+ in mitochondria to be a crucial signal in
ROS-mediated apoptosis [11]. Finally, neurones function and are
sustained in an adaptive cellular milieu comprised of a majority of
glial cells such as astrocytes [12,13]. Neurones may also be exposed to
cytokines produced by microglia and astrocytes in the inﬂammatory
phase of injury in the central nervous system [12,14], which can
activate extrinsic pathways to cell death. These aspects of the cellular
milieu of neurones are not dealt with in detail in this review.
Whilst post mortem human brain tissue or those from animal
models of injury or disease provide clues as to the diversity of
neuronal death, the clearest information about molecular mechan-
isms leading to death comes from laboratory studies at the cellular
level using cell models of injury or disease. Thus, detailed studies of
the molecular cell biology of appropriate cultured primary neurones,
or immortalized cells with neuronal properties, have enabled the
dissection of cellular responses and death outcomes schematically
represented in Fig. 1. There is an initial primary response to the trigger
that may be external (e.g. toxic molecules impinging on the cell) or
internal (e.g. inappropriate intracellular protein aggregation). The
primary distortion of cellular biochemistry and physiology, if not
rectiﬁed by the cell promptly and effectively, activates signalling
pathways (secondary response) that converge on mitochondria. Such
signalling upstream of mitochondria includes cooperative and
antagonistic interactions between Bcl-2 family members. These
mechanisms, together with any perturbation in function that
mitochondria may have directly sustained, culminate in an overall
processed signal (or the decision) that activates the mitochondria to
signal further downstream initiating one or more of the death
pathways [3,5,15]. In neurodegenerative disease involving protein
aggregation, ER stress may play an important role in pathways to
death. In this setting, damaged proteins also need to be eliminated
through the ubiquitin-proteasome system (UPS).
All these diverse signalling pathways, both upstream and down-
stream of mitochondria, seem to exhibit cross-talk. In other words, the
progression in one pathway may inﬂuence (positively or negatively)
progression of other pathways simultaneously. The outcome of these
complex interactions maybe such that in one initially homogeneous
population of cultured neurons exposed to a given treatment, there is
likely to be a heterogeneous set of responses between different cells of
that population. The recognition that individual cells may display a
subset of markers characteristic of explicitly deﬁned cell death
paradigms (e.g. PCD Types I, II or III) (Fig. 2) adds a further level of
complexity. This concept needs to be considered in concert with the
general notion of the potential of stressors to induce injury across an
insult-dependent apoptosis-necrosis continuum [16,17] and as a
consequence individual cells in the same treated population can lie at
a different end point within the continuum.
Severe injury or cellular damage may lead to unregulated necrosis,
called “accidental” [15,18] because cells subjected to extensive ionic
and water imbalance undergo rapid swelling leading to gross cellular
debilitation [17,19,20]. This severe cytotoxic outcome is distinguished
from programmed necrosis where there are distinct regulated
pathways (separate from both apoptosis and autophagy). Those
cells undergoing PCD-Type III bear some morphological resemblance
to truly necrotic cells but undergo a discrete loss of permeability of the
plasma membrane [18]. Cells undergoing either programmed or
unregulated necrosis seem both to lose mitochondrial energisation
and ATP production. Two proposed subsets of PCD-Type III, designat-
ed “necroptosis” [21] and “parthanatos” [22] are brieﬂy considered
herein below.
In the sections that follow, molecular and cellular details of the
pathways relevant to mitochondria in relation to neuronal cell death
are discussed. This mechanistic coverage is followed by consideration
of several scenarios of neurodegeneration and neuronal injury, in
which both the general principles above and the molecular pathways
Fig. 1. Diverse pathways leading to cell death. The schematic indicates key stages that
occur after a cell experiences a particular stressor from either outside or within the cell
(the death trigger). The primary response is elicited by the immediate perturbation of
cellular structures and functions. Subsequent intracellular signalling pathways are
activated (secondary response), which, after processing (e.g. through interaction of
competing members of the Bcl-2 family of proteins), lead to a “decision”. This
determines the adoption of one or more death pathways that result in the possible
outcomes listed at the foot of the schematic. Mitochondria play a key role in many of
these death pathways, which may operate through redistribution to the cytosol of
apoptogenic proteins. Other aspects of mitochondrial involvement (not shown here)
include disrupted energisation of these organelles (and consequent imbalances in ion
ﬂuxes and loss of ATP production) and generation of secondary ﬂuxes of ROS.
Endoplasmic reticulum (ER) stress is sometimes invoked, for example in protein
aggregation which becomes determinant when putative toxic protein intermediates
are not destroyed by the UPS. Cross-talk between pathways (double-headed horizontal
arrows) signiﬁes the upstream and downstream interactions between pathways.
Upstream cross-talk may inﬂuence the signal processing phase, and includes the
interactions between ER and mitochondria mediated by Ca2+; downstream cross-talk
affects the ﬁnal death mechanism andmorphological indications that typify the various
death modes. Caspase involvement is obligatory for “pure” apoptosis (PCD Type I), but
is less evident in other apoptosis-like outcomes. The currently applied various death
classiﬁcation systems are summarised below the schematic, embracing the PCD Type
nomenclature and the more recently deﬁned mechanistic terms for cell death modes
[12]. The concept of the apoptosis-necrosis continuum integrates the differential
involvement of these various death pathways and outcomes, to help explain the often
complex patterns of neuronal death (mix of PCD-Types I, II and/or III) as described in
more detail in the text. In unregulated (accidental) necrosis, there is a rapid general
breakdown of many aspects of cellular integrity. This characteristically includes
dissipated mitochondrial membrane potential (ΔΨm) with consequential losses of both
ion gradients across the IMM and ATP production.
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that present discrete neuropathologies.
2. Molecular aspects of pathways involving mitochondria that can
lead to neuronal cell death
2.1. Apoptosis
Most studies on cell death have focused on apoptosis (PCD-Type I)
which is dependent on caspase activation. Apoptosis is composed of two
main pathways, the extrinsic (death receptor pathway) and intrinsicpathways. Whilst the extrinsic pathway can bypass mitochondria, the
intrinsic pathway is deﬁned by the involvement of mitochondria. In the
latter pathway, apoptogenic proteins are redistributed to the cytosol
from the mitochondrial intermembrane space (IMS), leading to
activation of caspases that directly activate cell death. The initiation of
OMMP is regulated by the Bcl-2 family of proteins.
This family consists of three subfamilies, which are categorised
according to function and the presence of up to four Bcl-2 homology
domains (BH1-4) (reviewed in [23]). A hierarchy exists within the
Bcl-2 family ensuring that initiation of OMMP is a tightly controlled
process. At the top of the hierarchy is the pro-apoptotic BH3-only
subfamily, whose members are responsible for initiating the activa-
tion of other Bcl-2 proteins. These are divided into pro-apoptotic and
anti-apoptotic (pro-survival) subfamilies. The anti-apoptotic Bcl-2
proteins are the intermediaries between the BH3-only proteins and
the pro-apoptotic Bcl-2 family members, which include Bax and Bak.
One view is that the anti-apoptotic Bcl-2 proteins antagonise Bax and
Bak until the pro-survival proteins are deactivated by the BH3-only
proteins. Others argue that some BH3-only proteins also act as
facilitators, directly interacting with Bax and Bak to initiate their
activation (reviewed by [23]). Once activated, Bax and Bak change
conformation, oligomerise and form pores in the outer mitochondrial
membrane (OMM). The “pore” is likely to be lipidic in nature, thus
allowing transit of proteins from the IMS to the cytosol and vice
versa [5].
The key executioners that relocate to the cytosol from the IMS
(reviewed in [4,24]) include cytochrome c (cyt c), the IAP inhibitors
“second mitochondria-derived activator of caspases/direct inhibitor
of apoptosis-binding proteinwith low pI” (Smac/DIABLO) and HtrA2/
Omi that permit general caspase activation, and the caspase-
independent proteins, apoptosis inducing factor (AIF) and Endonu-
clease G (Endo G) [4,25–27]. Once redistributed to the cytosol, cyt c
forms a complex with Apaf-1 and ATP, named the apoptosome which
is responsible for activating caspase-9. Caspase-9 in turn activates
downstream effector caspase-3, caspase-6 and caspase-7, ultimately
causing chromatin condensation and DNA fragmentation (reviewed
in [24]). The redistribution of AIF and Endo G during apoptosis is often
observed as a late event, relative to cyt c and Smac/DIABLO
redistribution [25,26]. The activation of both AIF and Endo G results
in nuclear breakdown and DNA cleavage apparently without the
requirement of caspases [28]. Moreover, in an apoptotic setting, AIF
and Endo G are thought to act as part of a feed-forward mechanism
whereby their redistribution from mitochondria is triggered by
downstream caspase activation (reviewed in [29]).
In some settings (discussed below for programmed necrosis), the
release of AIF tethered onto the inner mitochondrial membrane
(IMM) requires calpains rather than caspases [30]. Furthermore other
IMS proteins are also tethered, such that cyt c needs to be released
from cardiolipin embedded in the IMM and Smac/DIABLO may be
bound to survivin in the IMS itself [5]. Therefore OMMP does not allow
unbridled redistribution of IMS proteins to cytosol, but other factors
may also be needed to disrupt tethering mechanisms.
A further feature of the systematic mitochondrial changes leading
to OMMP is the topological reorganisation of the IMM in some
situations. The IMM is normally impermeable to ions (including
protons) and when energized sustains an electrical potential (ΔΨm).
There is a complex apparatus in the IMM, the MPT pore, which is able
to undergo wide amplitude opening to totally dissipate ΔΨm. This
results in loss of energisation of the IMM, leading to an inability of the
mitochondria to sustain ion gradients and ATP production. This
complete MPT event arises from various stressors acting on
mitochondria and often characterises necrotic types of death (see
below), but is not a deﬁning feature of apoptosis. However, small
amplitude swelling (or MPT pore “ﬂickering”) can lead to transient
depolarization. This event is accompanied by gentle swelling of the
IMM allowing IMS proteins, such as cyt c (trapped deep inside cristal
Fig. 2. Typical markers of cell death in neurones undergoing various types of PCD. Cells illustrated here are primary cortical neurones from embryonic mice. Formarkers of PCD-Type I
cells were either untreated (controls) or treated with staurosporine (STS). Cyt c localisation (green) is observed in controls (A) as mitochondrial but in treated cells (B) as
redistributed throughout the cell; nuclei are stained with DAPI (blue). Further, caspase-3 activation (red) is not seen in controls (C) but is observed prominently in treated cells (D).
DAPI staining shows normal nuclei in controls (C) but condensed and fragmented nuclei in treated cells (D). For markers of PCD Type II, cells were either untreated (controls) or
treated with hydrogen peroxide. GFP-LC3 (green) is seen as diffusely distributed throughout the cell in controls (E) but as numerous puncta in treated cells (F). In cells showing GFP-
LC3 puncta, analysis of nuclear morphology after staining with propidium iodide (red), which diffuses into cells once the plasma membrane becomes permeabilised (G and H),
shows that cells may either contain condensed fragmented nuclei (G) or condensed but not fragmented nuclei (H). For markers of PCD Type III, cells were either untreated (controls)
or treated with hydrogen peroxide. Endo G localisation (red) is observed in controls (I) as mitochondrial but in treated cells (J) as redistributed diffusely throughout the cells, which
have become rounded. Plasma membrane permeabilisation does not occur in controls (K) as evidenced by exclusion of propidium iodide (red); the differential interference contrast
image is shown to reveal the cell population in this ﬁeld. However, at relatively early times (4 h) of treatment (L), uptake of propidium iodide occurs in themajority of cells. Bars in all
micrographs indicate 10 μm. Arrows indicate index cells that demonstrate the described features. Detailed methods for cell treatment, analysis, microscopy and imaging are as
published [27,322]. GFP-LC3 images are from Higgins, G.C. and Nagley, P., unpublished data.
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OMM as the invaginations disappear with IMM expansion (reviewed
by [5]).
The features outlined above are derived from several mammalian
systems and apply generally to the intrinsic pathway observed in
neurones. Particular members of the Bcl-2 family are recognised as
prominent in neurones, such that Bax rather than Bak often induces
apoptosis [31]. Further, in neurones, p53 has been implicated in up-
regulating the BH3-only proteins PUMA, Noxa and Bid as well as Bax
(reviewed in [32]). While Noxa does not appear critical for neuronal
apoptosis [33–35], PUMA and Bid evidently often initiate OMMP.
In neurones of various types, including cortical, hippocampal and
sympathetic neurones, PUMA has been shown to localise to
mitochondria during apoptosis and interacts speciﬁcally with Bcl-XL
and Bax [33,35,36]. Under oxidative stress conditions PUMA is
upregulated and controls the activation of Bax [33,36]. Likewise p53
activation resulting from DNA damage also triggers activation of
PUMA and apoptosis in superior cervical ganglion neurones [35].
PUMA and p53 are also engaged during ER-stress induced neuronal
apoptosis [37,38]. However PUMA is not involved in apoptosis
induced by excitotoxicity, highlighting the speciﬁcity of PUMA
recruitment to the type of insult involved [37,38].
Bid is another BH3-only protein regulated by p53 and is also
responsible for the activation of Bax at the mitochondrial level during
OMMP in neurones [39]. Such Bid activation requires it to be
truncated (generating tBid), carried out by active caspase-8 or
caspase-2 [40,41], as with other mammalian cell types. In neurones
tBid is critical for apoptosis to occur under conditions of focal cerebralischaemia and oxygen/glucose deprivation [42,43]. Once translocated
to the mitochondria, tBid is directly involved in the redistribution of
AIF to the nucleus in cultured neurons [44,45]. However, recently it
was demonstrated that full length Bid is also capable of inducing
caspase-independent cell death in neurones [40,46]. These ﬁndings
imply that Bid does not require truncation to be activated in neurones,
and that it may have an important role in the redistribution of AIF
during cell death in the absence of caspase activity.
Amongst the various apoptogenic IMS proteins that are redis-
tributed during neuronal apoptosis, cyt c and AIF appear to play
deterministic roles [25,26]. The role of cyt c in activating caspase-9
(and subsequently caspase-3) has been well documented in neurones
[25,26,47]. Likewise, particular attention has been paid to the role of
AIF in inducing caspase-independent apoptosis [48]. Indeed, AIF is a
critical component of neuronal apoptosis, as shown by studies
utilising AIF-deﬁcient harlequin mice and cyclophilin A -/- mice
(the latter being required for AIF translocation) [49,50]. Recent
studies have suggested that AIF may also be a major player in
programmed necrosis (see below). Under conditions that induce
caspase-dependent death (PCD-Type I), AIF involvement has been
noted as a late event, following the initial activation of caspase-3 in
cortical neurones and cerebellar granule cells [25,26]. This is
presumably due to the need for caspases to untether AIF from the
IMM. The redistribution of both Smac/DIABLO and HtrA2/Omi has
been documented in neurones, during apoptosis [25]. However,
neither is critical for neuronal apoptosis, indicating that these
apoptogenic proteins are merely facilitators of neuronal cell death
[51–54]. Similarly, Endo G has been shown to relocate from the IMS
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apoptotic induction [27]. Overall, recruitment of the intrinsic
mitochondrial pathway to effect pure apoptosis appears a less
common event than initially believed in neuronal injury (see
below), being more likely to occur at low stress intensity in the
insult-dependent apoptosis-necrosis continuum [16,17]. However,
apoptosis is induced by discrete forms of stress, particularly in the
immature brain and during trophic factor-dependent developmental
PCD [6,19,26,28].2.2. Autophagy
Autophagy is best known as the process by which molecules and
organelles undergo lysosomal clearance/degradation in order to help
maintain cellular homeostasis. Autophagy is of recognized importance
in the central nervous system [55]. While autophagy can manifest
itself via several different pathways (reviewed in [56]), macroauto-
phagy (MA) is the typemost commonly associated withmitochondria
and cell death and will be considered in detail here. Other autophagic
pathways include microautophagy (autophagy without vesicles) and
chaperone-mediated autophagy (CMA), and consideration of these
processes is left till relevant sections below. “Autophagy”will be used
here in reference to MA except where speciﬁcally identiﬁed
otherwise. Autophagy involves the formation of a double membrane
vesicle known as an autophagosome, which sequesters and engulfs
organelles or molecules and transports them to lysosomes for
degradation. This process has been widely studied by monitoring
the recruitment to these vesicles of microtubule-associated protein 1-
light chain 3 (LC3), an essential protein component of the autophago-
some membrane [57]. Due to the post-mitotic nature of neurones,
there is thought to be heightened emphasis for autophagy tomaintain
homeostasis of functional organelles, such as mitochondria [58]. The
prominence of autophagy in neurones can be attributed to the lack of
cellular division, which contributes to the build-up of dysfunctional
mitochondria and protein aggregates (i.e. β-amyloid or α-synuclein
(αSN) in Alzheimer's disease (AD) and Parkinson's disease (PD),
respectively), thought to lead to neuronal cell death (reviewed in
[58,59]). There are at least two routes involving autophagy to cell
death in neurones. Firstly, when the autophagic process is insufﬁcient
to deal with toxic protein aggregates, as possibly occurs in AD and PD
(reviewed in [60]). Secondly, the up-regulation of autophagy that is a
direct contributor to cell death as in PCD Type II. Adding further
complexity to this paradigm has been the recent discovery of
cross talk between autophagy and the apoptotic pathways (Fig. 1).
The recent recognition of autophagy as a cell deathmechanism has
seen a huge expansion of effort in this area. However, it has been
noted that an enhancement of autophagic activity alone during cell
death is insufﬁcient to constitute PCD-Type II [60]. To meet the test of
authentic autophagic cell death [15], it is necessary to demonstrate
that down-regulation of key proteins essential for autophagy arrest
cell death, as has been shown in variousmammalian cell systemswith
Beclin-1, Atg5 or Atg7 [61,62].
The importance of PCD-Type II in neurones has only recently been
appreciated. Autophagic neuronal cell death was ﬁrst suspected a
decade ago with the discovery that an alternative death pathway was
activated in the absence of apoptosis in sympathetic neurones [63].
However, while there have been several neuronal studies implicating
PCD-Type II since then,most are not deﬁnitive in the above-mentioned
terms in deﬁning death as autophagic. Such studies have reported
formation of multiple vesicles [64], the up-regulation of autophagic
proteins [65] or inhibition of death with autophagic inhibitors [63,64].
Use of these inhibitors, such as 3 methyladenine or wortmannin, may
also block apoptotic pathways [66]. Thus, many neuronal studies to
date have lacked the sophistication required to conﬁrm PCD-Type II as
an independent cell death mechanism (see section 4.1).The concept that mitochondria are central to the cell death
decision process (Fig. 1) also has relevance to autophagic cell death,
speciﬁcally in relation to the process of mitochondrial autophagy or
mitophagy (reviewed in [67]). Mitophagy is deﬁned as the selective
degradation of mitochondria by autophagy, but the mechanism of this
process remains unclear. For example, it is not well understood how
mitophagy is able to selectively target mitochondria, and the cellular
role needs clariﬁcation, i.e. whether mitophagy is beneﬁcial or
detrimental. Nevertheless, some insight into the role of mitophagy
in neurones and other mammalian cell types has been obtained.
Mitochondria which are depolarised, or those associated with Bax,
have been suggested to possess a propensity to be cleared via
mitophagy in the absence of caspase activation during cell death
(reviewed in [67]).
The process of mitophagy has been suggested in rat cortical
neurones, with increased observations of autophagy associated with
oxidative damage to mitochondria [68]. Moreover, the clearance of
mitochondria that contain the ubiquitin ligase Parkin, a protein
implicated in familial PD, provides evidence for mitophagy in a
pathological neuronal setting [69]. The relocalisation of Parkin from
the cytoplasm to themitochondria was followed by the disappearance
of mitochondrial markers concomitantly with the appearance of
numerous lysosomes within cells. A further link between PD and
mitophagy has been shown in neuroblastoma cells treated with 1-
methyl-4-phenylpyridinium (MPP+) that is the active species of the
PD toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This
treatment resulted in an increase in autophagy and a loss of the
mitochondrial proteins, pyruvate dehydrogenase E2 and mitochon-
drial membrane protein p110 [70]. Here, mitophagy appeared to be
regulated by MEK/ERK signalling pathway downstream from
mitochondria.
Another example of cross-talk involving mitochondrial regulation,
autophagic players and cell death involves Beclin-1. This protein is a
central component of the autophagic pathway and itself contains a
BH3-only domain [71]. A role for Beclin-1 in PCD-Type II is directly
supported by evidence that its over-expression induces massive
autophagy followed by cell death [72]. Beclin-1 is negatively regulated
by interacting with the anti-apoptotic Bcl-2 or Bcl-XL proteins;
autophagy in parallel is induced by the competitive disruption of
this interaction by BH3-only proteins such as Bad [73]. Moreover,
disruption of these Bcl-2 family/Beclin-1 interactions by mutation of
the BH3-only domain within Beclin-1 led to active autophagic death
[72]. The identiﬁcation of such interactionsmodulating autophagy has
rendered earlier notions that Beclin 1 directly regulates apoptosis as
being less likely. The current view is that cross-talk is unidirectional
[73,74], such that Bcl-2 family inﬂuences autophagy but Beclin-1 does
not inﬂuence apoptosis. An interesting side-play to these interactions
can be noted in relation to autophagy under starvation conditions in
which autophagy can be beneﬁcial to cellular homeostasis, rather
than leading to cell death. Thus, in starved HeLa cells, ABT737 (a BH3-
only peptidemimetic) inducedmitophagy but not reticulophagy (also
known as ERphagy), yet only ER-targeted Bcl-2/Bcl-XL (not mito-
chondrially targeted Bcl-2/Bcl-XL) was capable of inhibiting starva-
tion-induced autophagy [75]. These interactions may be relevant to
ER-stress/autophagic cross-talk discussed below.
Further interplay between the apoptotic and autophagic pathways
exists via death signalling molecules such as the autophagy protein
Atg5, as well as the BH3-only proteins BNIP3 and BIK. In its capacity as
an autophagy protein, Atg5 is essential for autophagosome formation
[76]. However, Atg5may undergo truncation by calpains, converting it
to an effective apoptotic inducer [77]. Once truncated, Atg5 has been
shown to translocate from the cytosol to mitochondria, where it
associates with Bcl- XL, triggering cyt c redistribution and down-
stream caspase activation [77]. Hypoxia in HEK293 cells up-regulates
BNIP3 as well as effecting cell death [78]. Overexpression of BNIP3
induced autophagy, while silencing its expression resulted in a
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ingly, knockdown of Beclin-1 and Atg5 in this same system also
reduced hypoxia-induced cell death, suggesting that all three proteins
may be involved in the same cell death mechanism. BIK, another BH3-
only protein, has also been linked to PCD-Type II in Bcl-2 -/- murine
embryonic ﬁbroblasts. In this model, cell death triggered by ectopic
expression of BIK was attenuated by autophagic inhibitors and
silencing of Beclin-1 and Atg5 [79]. Autophagy may be activated by
relevant Bcl-2 family members during cell death as a means for
triggering additional supply of energy required to drive apoptosis to
completion.
2.3. Programmed necrosis
The concept of programmed necrosis (or PCD-Type III) is less well
characterised than the other two types of PCD. Programmed necrosis,
as mentioned in the introductory overview (section 1), has similar
hallmarks to “accidental” necrosis with the major distinction being
that the former is a regulated process which can be arrested. As with
PCD-Type I and PCD-Type II, mitochondria are also the hub of cell
death regulation in programmed necrosis. PCD-Type III is not
dependent on caspase activation [15], unlike PCD-Type I (Fig. 1).
Programmed necrosis implicates the MPT and is reliant on AIF and
Endo G redistribution [18,27]. A family of cysteine proteases, called
calpains, which are dependent on Ca2+ for activation are often
involved in PCD-Type III [15,80]. Finally, a subclass of programmed
necrosis, coined “necroptosis” [21] has been identiﬁed which requires
Receptor interacting protein-1 (RIP-1) [81], which has also been
implicated in MPT activation.
Through studies focusing on the role of cyclophilin D (CypD) as a
component of the MPT pore, this protein has been shown to have a
speciﬁc role in regulating necrotic death, but not apoptosis. In non-
neuronal cells, MPT (and consequently the loss of ΔΨm) is blocked in
cells from mice deﬁcient in CypD; under these conditions some types
of necrotic cell death, but not apoptosis were prevented [82,83].
Moreover, over-expression of CypD in B50 neuronal cells promoted
MPT and necrosis after nitric oxide (NO) treatment, but inhibited
staurosporine-induced apoptosis [84]. In non-neuronal studies RIP-1
has been demonstrated to translocate to the mitochondria where it
can initiate necrotic cell death, regulating the interaction between
CypD and adenine nucleotide translocase [85].
As mentioned necroptosis, a subtype of PCD-Type III, involves the
serine/threonine kinase RIP-1 [86]. Necroptosis has been demon-
strated to be involved in delayed cell death after ischaemic brain
injury in mice, which can be blocked by the necroptosis inhibitor,
Necrostatin-1 (Nec-1) [21]. Nec-1 has been shown to inhibit RIP-1
[81], as well as reducing ROS levels in neuronal cells, acting upstream
of the ROS production, rather than scavenging ROS directly [21,87].
Necroptosis has also been shown to be induced by NMDA-excitotoxi-
city in rat cortical neurones [88]. In this study a subpopulation of
neurones were thought to undergo necroptosis in response to NMDA-
excitotoxicity which was inhibited by Nec-1. As with PCD Type I and
PCD Type II, Bcl-2 family members can modulate PCD-Type III. Thus, it
has recently been shown that necroptosis may also be regulated by
the BH3-only protein Bmf [89]. Knockdown of Bmf in L929 cells
directly inhibited necroptosis but not apoptosis, although Bmf has also
been reported as a pro-apoptotic protein in other studies [90,91].
Calpains are Ca2+-dependentproteases,whichhavebeen implicated
in all the PCD pathways that exist across the apoptosis-necrosis
continuum (Fig. 1). While calpains have been reported to be involved
in apoptosis, for example in studies on motor neurones (MNs) [92–94],
these proteases aremore generally prominent in programmed necrosis,
where intracellular Ca2+ levels are elevated [95–97]. Calpains include
several tissue-speciﬁc isoforms (n-calpains) and two ubiquitous
isozymes, calpain I (μ-calpain) and calpain II (m-calpain) that are
activated in vitro bymicromolar andmillimolar concentrations of Ca2+,respectively [30]. Compared with caspases, calpains do not have strict
cleavage speciﬁcity, and their activity is tightly regulated by cofactors,
such as the endogenous inhibitor, calpastatin, and phospholipids [98].
Some cross-talk between caspase-dependent and caspase-independent
PCDpathways is evident fromobservations that calpastatin is cleavedby
caspase-3 and that this cleavage is essential for regulation of calpain
activity during PCD-Type I [99,100]. In a model of experimental
hypoglycaemia, neuronal death is dependent on both MPT and
redistribution of cyt c and AIF, and apparently involves both caspase-3
and calpain activation [101]. Furthermore, calpain I is directly involved
in the redistribution of AIF from isolated mitochondria [30].
Much attention has been paid to the role of AIF during
neuronal cell death. Many studies reported involvement of AIF in
the completion of caspase-independent cell death in neurones
[25,26,48–50,102–104]. Only recently has AIF-dependent death (in
the absence of caspase activation) been recognised as programmed
necrosis [18]. Other studies of neuronal cell death in which AIF
redistribution occurred early, associated with calpain activation, and
relatively weak caspase involvement, may now be redeﬁned as PCD-
Type III [95]. Whether Bid is involved in the redistribution of AIF
under PCD-Type III conditions, as has been reported in apoptosis or
whether calpain I acts alone in its relocation is currently not clear
[30]. Interestingly, herein calpain inhibition prevented AIF release
from isolated mitochondria, underscoring the signiﬁcance of
calpains in caspase-independent cell death. In another study, over-
expression of calpastatin, an inhibitor of calpains, was observed to
reduce kainate-mediated excitotoxicity in vivo, which was directly
associated with a reduction in cleavage of Bid to tBid and the redis-
tribution of AIF and Endo G frommitochondria [28]. Poly(ADP-ribose)
polymerase 1 (PARP-1)-mediated neuronal injury was recently de-
ﬁned as a caspase-independent, AIF-dependent type of PCD termed
“parthanatos” [22] and its characteristics are suggestive of programmed
necrosis [18]. Ca2+ dysregulation may be a key event here, but it
remains unresolved whether calpain triggers AIF redistribution in
intact neurones, although potentially calpain-dependent or calpain-
independent pathways could operate in parallel [105,106].
Until recently, the role of Endo G in PCD has been unclear, due to
conﬂicting reports on its signiﬁcance in apoptosis [107–109]. In
neurones Endo G translocates to the nucleus during cell death,
although it is uncertain whether it is active in these systems
[28,110,111]. Recently, Endo Gwas shown to be required for PCD Type
III in cortical neurons under oxidative stress on the basis of siRNA-
mediated down regulation of Endo G [27]. This ﬁnding has brought
new focus to the role of Endo G in PCD, because suppression of Endo G
did not affect cell progression to PCD Type I induced by staurosporine
[27]. The co-existence of the two pro-death proteins AIF and Endo G
offers multiple routes to demise and thus greater certainty of
elimination of “at risk” neurones, raising the possibility that each
might be responsible for eliciting cell death under varying conditions.
Indeed, one possibility is that Endo G redistribution has a speciﬁc role
in completing PCD-Type III, but is a passive event during PCD-Type I.
3. ER stress
In neurones, as in all eukaryotic cells, the ER is important for the
synthesis, folding and post-translational modiﬁcation of transmem-
brane and secreted proteins [112]. The ER also serves as the major
cellular Ca2+ store and the site of biosynthesis of steroids, cholesterol
and other lipids, thus playing a crucial role in organelle biogenesis and
signalling [113]. ER stress is caused by a perturbation of any of these
major functions of the ER, and accumulation of unfolded proteins in
the ER lumen is a shared hallmark of disturbance of these functions.
Normally, the protein folding capacity of the ER is dynamic and alters
according to the ﬂux of unfolded polypeptide chains entering the ER.
Such homeostatic control is achieved through the combined actions of
signal transduction pathways named the unfolded protein response
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deprivation or alterations in the redox state of the ER, secretory
protein synthesis or intracellular Ca2+ concentrations [115].
The principles of the UPR are now relatively well deﬁned and have
been detailed in recent reviews [112,114]. At least three distinct
signalling pathways are involved, and each one is mediated by ER
integral membrane proteins that sense the protein folding status in
the lumen and transmit this information to the cytosol. These UPR
sensor proteins are activating transcription factor 6 (ATF6), PRK-like
ER kinase (PERK), and inositol-requiring kinase 1 (IRE1) [116–118].
The ER chaperone, immunoglobulin-binding protein (BiP), plays a
central role in activation of each UPR sensor by detecting misfolded
proteins in the ER. Under normal conditions, BiP binds to each UPR
sensor. However, when misfolded proteins are present in the lumen
[112], BiP binds preferentially to these proteins, and is released from
each UPR sensor, resulting in their activation.
The ﬁrst two responses of the UPR act to relieve ER stress and to
thus promote survival of the neurone. Firstly, activation of PERK
results in a reduction in the load of protein entering the ER by
inhibition of cellular protein translation [119]. This step prevents
further protein synthesis when the ER lumen is already overloaded
and compromised in its folding capacity. The second pro-survival
response, mediated by both IRE1 and ATF6 pathways, results in an
increase in the capacity of the ER to handle unfolded proteins. UPR
chaperones, such as BiP, calreticulin, calnexin and the protein
disulphide isomerase (PDI) family members, are upregulated to
enhance the protein folding capacity of the ER [112,114]. The UPR also
removes misfolded proteins from the ER by enhancing proteolytic
degradation. There are two possible routes; (i) ER-associated protein
degradation (ERAD), whereby proteins are retro-translocated from
the ER lumen into the cytosol for degradation by the UPS [112,114],
and (ii) autophagy, whereby regions of the ER are targeted to
lysosomes or vacuoles, as discussed in more detail (section 2.2) There
is a functional link between ER stress and the UPS; induction of the
UPR leads to an accumulation of ERAD substrates and compromised
UPS [120]. Autophagy may serve as a mechanism to eliminate
portions of damaged ER under stress conditions or to control the
rate of ER expansion [33] and thus promote survival upon ER stress in
mammalian cells [121,122]. However, it is not yet clear how much
autophagy contributes to the clearance of misfolded proteins from the
ER during UPR induction [123]. Also this process appears to be a novel,
ER-speciﬁc type of autophagy that has been termed ERphagy [121], in
which the autophagosomes containing sequestered ER are not
degraded by vacuolar proteases until the stress is abolished. Beclin-
1 is essential for the initiation of autophagy and is regulated at the ER
membrane by Bcl-2 proteins, suggesting that signalling events
originating from the ER are essential for autophagy.
Interestingly, recent evidence of cross-talk between autophagy
and ER stress has emerged in the context of tumorigenesis through
the analysis of p62 [124]. Thus, genetic ablation of autophagy led to
accumulation of p62, ER chaperones, damagedmitochondria and ROS.
Further, in studies on aggregation-prone proteins relevant to HD,
inhibition of autophagy with consequent increases in p62 was shown
to increase the levels of proteasomal substrates because of blockage in
the UPS [125]. Of further neuronal relevance, autophagic degradation
of aggregated proteins requires functional multivesicular bodies
(formed from elements of the endosome pathway) and, under
conditions of autophagic blockade, protein aggregates form that
include ubiquitinylated proteins and p62, among others [126].
Therefore p62 is a key regulatory molecule linking autophagy and
other cellular mechanisms for eliminating damaged proteins.
The third response of the UPR occurs when the ER stress is
prolonged or severe and homeostasis cannot be re-established. PCD is
triggered, presumably to protect the organism from cells containing a
potentially toxic load of misfolded proteins. The molecular mechan-
isms that link protein misfolding at the ER to PCD have not been fullydeﬁned. However, it is clear that PCD pathways that are either
dependent on, or independent of, mitochondria are triggered by ER
stress, originating from all three branches of the UPR [127].
Accumulating evidence indicates that members of the Bcl-2 family
are located at the ERmembrane andmediate PCD induced by ER stress
[128]. The BH3-only proteins PUMA and NOXA are transcriptionally
induced during ER stress, through the tumour suppressor p53
[127,129–131]. Further, Bim is upregulated in response to ER stress
both transcriptionally and at the protein level, by inhibition of
proteasomal degradation [131]. The C/EBP homologous protein
(CHOP) is a pro-apoptotic transcription factor strongly induced by
ER stress (reviewed in [132]). Expression of CHOP leads to
translocation of Bax from the cytosol to mitochondria [133], down-
regulation of Bcl-2 [133] and up-regulation of BIM mRNA [131].
Moreover, in vivo studies show cells deﬁcient in any of Bim, CHOP or
Bax/Bak are all resistant to ER stress-induced apoptosis [128]. Other
BH3-only proteins, Bik and Spike, also localise to the ER [134].
Together these data demonstrate a direct connection between
activation of the UPR and the core mitochondrial PCD program.
All three UPR pathways activate both protective and apoptosis-like
responses and, as a consequence, the initial triggers that activate PCD
in ER stressed cells are not fully understood. Recently, it has been
proposed that the balance between cell survival and cell death is
facilitated by the relative levels of pro-apoptotic and pro-survival Bcl-
2 proteins at the ER membrane [114,135]. Tilting the balance towards
PCD may take time, perhaps explaining why prolonged UPR is
necessary for cell death. An alternative explanation is that the levels
of CHOP mediate the transition from pro-survival to pro-apoptosis.
CHOP mRNA and protein are both relatively unstable compared to
other UPR proteins; hence, prolonged ER stress may be required
before a critical threshold for cell death is reached [136]. Another
possible mechanism for the control of ER stress-induced PCD is direct
protein-protein interactions involving IRE1. Bax and Bak bind directly
to IRE1 at the ER, promoting its activation, and this interaction
modulates cell survival [137]. This action is in contrast to the pro-
apoptotic effect of Bax and Bak at the mitochondria, suggesting a
compartmentalisation of function. Recently it was demonstrated that
Bax inhibitor-1 (BI-1) also physically interacts and inhibits IRE1 [135],
thus facilitating further control and cross talk between the UPR and
PCD.
PCDmay also result from proteolytic activation of speciﬁc caspases
located in the ER. Caspase-12 in rodents is bound to the ER membrane
and may be activated by a similar process to the death receptor
pathway. Activated IRE1 recruits TNF receptor-associated factor 2
(TRAF2) from pro-caspase-12, resulting in its activation, leading to
subsequent cleavage of caspase-9 and caspase-3 independent of
classical activation of the intrinsic mitochondrial pathway. In humans,
caspase-4 may substitute for caspase-12 because deletions are
present in the human caspase-12 gene homologue [138,139].
However, although caspase-12 and caspase -4 are widely used as ER
stress markers, their role as initiators of ER stress-induced cell death
has been refuted [140,141]. Although poorly understood, activated
IRE1 has also been implicated in ER stress-induced activation of the c-
Jun N-terminal kinase (JNK), ERK and NF-κB pathways, leading to PCD
[142–144].
The ER represents the primary store for Ca2+ in the cell, andwithin
the ER Ca2+ functions in protein folding by binding and modulating
the activity of ER chaperones such as calnexin and calreticulin.
Mitochondria act as an important intracellular buffer for Ca2+ signals
emanating from the ER and recycle Ca2+ back to the ER [134].
Reciprocally, adjustments in Ca2+ levels within the mitochondria can
regulate respiratory activity. Hence, the ER and mitochondria are
closely coupled at several contact points.
In more speciﬁc terms, mitochondrial Ca2+ is regulated by a
repertoire of Ca2+ inﬂux and efﬂuxmechanisms across the IMM [145],
including a diacylglycerol-sensitive channel associated with inositol-
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perhaps involving Ca2+ microdomains [146], provides an early point
of ER-mitochondrial interaction relevant to matrix Ca2+, which may
trigger PCD as follows. ER stress induces the release of Ca2+ from the
ER lumen, leading to PCD via Ca2+-dependent mechanisms involving
ER channels such as IP3R [147,148], or the ryanodine receptor
[149,150]. ER stress can also trigger prolonged Ca2+ accumulation in
the mitochondrial matrix, leading to PCD via a voltage-dependent
anion channel and IP3R-dependent process [151].
UPR mechanisms have mainly been elucidated in cultured non-
neuronal cells expressing high levels of protein, although a handful of
studies have been speciﬁc to neurones [152,153] and reviewed in
[154]. The exact role of the UPR in the central nervous system in
normal physiology is unknown but probably involves the early,
protective components of the UPR. Due to their unique properties,
neurones may be more susceptible to ER stress triggered by speciﬁc
events, such as dysfunction of intracellular trafﬁcking or Ca2+
buffering, compared to other cell types. Neurones also contain ER
not only in the soma, but also in the dendrites [153]. The role of the ER
stress in inﬂuencing cellular life/death decisions has led generally to
much interest in the link between UPR signalling and human diseases
that arise from pathological conditions eliciting ER stress. Despite
their differing phenotypes, neurodegenerative diseases such as ALS,
AD and PD share common neuropathological features, including the
presence of insoluble aggregates of abnormally misfolded proteins.
While the misfolded protein differs in each disorder, the common
feature is protein misfolding involving neurones. Nonetheless, the
insoluble aggregates in any one disease may be comprised of multiple
proteins, some of which are common to the aggregates observed in
different neurodegenerative disorders [155,156].There is now sub-
stantial evidence that UPR is involved in the death of neurones in
many neurological conditions (reviewed in [157] and discussed in
more detail below), and also in acute brain disorders such as
ischaemia [154].
Proteins are also synthesized and folded in the mitochondria as
well as in the ER and cytosol and a similar pathway responds to
mitochondrial stress, the mitochondrial unfolded-protein response
(UPRmt) [158]. The molecular mechanisms underlying this process
are unclear, although recent studies suggested that the pathway starts
with stress detection in the mitochondrial matrix followed by
activation of UPRmt targets in the nucleus [159].4. Multifaceted PCD in acute and chronic neurodegeneration
4.1. Oxidative injury
Oxidative stress has been reported to occur in many different
pathological conditions within the brain. Such circumstances include
chronic neurodegenerative disorders such as PD (reviewed in [160])
and more acute settings such as the period directly following
ischaemia-reperfusion injury (reviewed in [161]). The contribution
that oxidative stress makes in triggering cell death in the brain
remains unclear and it is uncertain if it alone is a sufﬁcient trigger in
pathological conditions. A major internal source of ROS in neurones
is thought to result from escaping electrons from the respiratory chain
within mitochondria reacting with oxygen (reviewed in [162]). These
ROS in turn cause damage to DNA, proteins and lipids. Other
contributions to the oxidative load may be through metal ion-
associated Fenton reactions, lipid peroxidation, contributions of
matrix enzymes (especially 2-oxoglutarate dehydrogenase complex)
and nitric oxide-induced protein nitrosylation [10,162,163]. The type
of ROS and the load of individual reactive molecules are generally
accepted to play a determinant role in the death outcome. Indeed, it is
now apparent that ROS have the capacities to induce diverse patterns
of PCD.In response to small or relatively low doses of oxidative stress,
neurones are capable of activating the intrinsic apoptotic pathway
[25]. In neurones, ROS can elicit p53 activation which in turn can
upregulate the BH3-only protein PUMA [36], which has been
demonstrated to translocate to the mitochondria and activate Bax
under these conditions [33,36]. The initiation of OMMP results in the
redistribution of pro-apoptotic factors such as cyt c, Smac/DIABLO and
HtrA2/Omi which are essential for the activation of downstream
effector caspase 3 and caspase 7, which ultimately lead to cell death
[25,164]. However, under higher levels of oxidative stress, which may
in itself inactivate caspases [165–167] or lead to a decrease in ATP
production due to mitochondrial damage (reviewed in [9]), activation
of alternate cell death pathways to apoptosis, including PCD-Type II or
PCD-Type III, is a more likely outcome [19,20].
The induction of autophagy during oxidative insult has been well
documented in other cell types (reviewed in [168]). NGF-deprived
sympathetic neurones can accumulate mitochondrial ROS, which
results in lipid peroxidation and the loss of IMM lipid cardiolipin and
ultimately autophagic cell death [169]. Oxidative stress has also been
reported to induce lysosomal dysfunction resulting in neuronal death
(reviewed in [170]). However these limited neuronal studies
involving oxidative stress have not explored autophagic cell death
as an alternative death mechanism to apoptosis. We have shown that
in response to oxidative insults such as hydrogen peroxide and
superoxide, there is minimal caspase activity, while autophagy
activity is elevated as shown by autophagosome formation and
conversion of LC3-I to LC3-II (Higgins, G.C., Devenish, R.J., Beart, P.M.
and Nagley, P., unpublished data). Furthermore this increase in
autophagic activity correlated with the increase in loss of membrane
integrity associated with cell death. Here, autophagic cell death was
conﬁrmed by the inhibition of cell deathwith the autophagic inhibitor
3-methyladenine and by silencing the autophagic proteins Beclin-1
and Atg7 with siRNA.
Themost pertinent of the three PCD pathways to oxidative stress is
likely to be PCD-Type III [171], particularly since necrosis is the most
commonly reportedmorphological outcome to oxidative insult. While
it is possible that unregulated necrosis has occurred in many previous
neuronal studies involving oxidative stress, the recognition of
programmed necrosis (PCD-Type III) has driven our recent work
demonstrating that under hydrogen peroxide insult the death of
mouse cortical neurones is dependent on Endo G in the absence of
downstream caspase activity [27]. While AIF has been widely
implicated as a caspase-independent cell death signal in neurones
[48,102,172], it has not been reported to act as a death executioner
under oxidative stress conditions. This may be the result of AIF acting
primarily as an antioxidant under these conditions (due to its
oxidoreductase function which allows it to clear H2O2 [172]) which
thereby obstructs it from performing its cell death function.
4.2. Hypoxic-ischaemic injury
Stroke is one of the most common forms of acute neurological
insult in adults and, while different from HI injury in infants and
children, they appear to share common but differentially recruited
patterns of PCD. Ischaemia involves complete arrest of circulation, but
inmiddle cerebral artery occlusion blood ﬂow is differently reduced in
various brain areas [173], so the pathobiochemical cascade and
cellular response would be expected to differ markedly across brain
regions. Injury in human brain and in animal models of HI has been
considered for some 10 years to involve a mix of types across the
apoptosis-necrosis continuum, with apoptosis in the penumbra and
necrosis in the core of the injury [174]. Only recently, with our
improved understanding of the complexities of PCD, have the
complexities of recruitment of diverse injury cascades, often in
parallel or overlapping, been appreciated in the evaluation of HI injury
[19,20].
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neuronal changes are considered to predominate in the infarct
periphery [175,176]. However, apoptotic cell damage (DNA fragmen-
tation and apoptotic morphology), concomitant with necrotic cell
loss, was found in autopsied brain tissue from a cohort of human
ischaemic stroke patients [177]. Recent evidence in autopsied brain
tissue from stroke patients suggests involvement of mitochondrial
signalling in the pathobiology [178]. The ﬁrst large-scale microarray
report showed alterations of many genes following human stroke,
including genes involved in apoptosis and cytoprotection, and
although differences were found compared with data from HI rat
brain many overlapping genes were identiﬁed [179]. In hippocampus
and cortex of neonatal rat, HI-induced injury involved neurones
predominantly exhibiting mixed features of apoptosis-necrosis
despite the presence of caspase-3. Early mitochondrial swelling
with Ca2+ deposits could, by analogy to adult brain, be associated
with cyclosporine-sensitive MPT [180]. However, classical apoptotic
morphologies were rare observations in neonatal HI models, whereas
older animals all exhibited predominantly necrosis [181]. However,
others believe the pattern of death to be neither apoptotic nor
necrotic, but to be novel and the morphology was not that of rupture,
but rather a shrinkage-type of necrosis [182].
Interruption of cerebral blood by HI insults produces reduced
glucose supply to the brain, marked reduction of mitochondrial
respiration and ATP deﬁciency leading to energy crisis. Subsequent
disruption of membrane ion pumps, plus increased cellular Ca2+
mobilization after its entry through over-activation of L-glutamate
receptors, can potentially elevate mitochondrial Ca2+ resulting in MPT
[183], generation of ROS, NAD+ depletion and PARP-1 activation
[145,184]. Although the involvement of Δψm and subsequent rupture
of the OMM remains controversial in PCD, elevatedmitochondrial Ca2+
can induce MPT and some forms of apoptosis can be inhibited by
cyclosporine, which binds to CypD in the MPT pore. Moreover,
cyclosporine inhibits MPT and is neuroprotective against ischaemic
brain injury [185,186]. CypD-knockout mice display a dramatic
reduction in the size of brain infarcts [187]. Collectively, events
consequent to elevated cellular and mitochondrial Ca2+ will activate
the intrinsic mitochondrial pathway and the redistribution of Ca2+ to
cytosol activating various processes, including ER-based mechanisms
and calpain-mediated redistribution of AIF [30]. While Δψm may
contribute here, Bax and Bid are known to redistribute and be recruited
to mitochondria during HI [44,188] and can be sufﬁcient signals to
initiate PCD. Emerging evidence indicates that both caspase-dependent
and caspase-independent signalling contributes to HI-induced cell
death, which occurs across the apoptosis-necrosis continuum depen-
dent on cell type and energy availability [49,103,189–193].
Many components of UPR (CHOP, BiP, PDI, caspase-12) are
activated in ischaemic injury [194]. ER-mediated injury with up-
regulation of UPRmarkers has been studied during ischaemic injury in
cultured neurones [20,194]. In models of either focal or global
ischaemia, up-regulation of UPR markers is dependent upon the
model, severity of insult and the neuronal population under study
[195–199]. Indeed, it has been suggested that the level of UPR
response after brain ischaemia and reperfusion may be important in
the extent of reperfusion neuronal death [200].
Autophagy is an adaptive strategy by which cells survive
bioenergetic crisis and thus should be especially relevant to HI injury
where ATP depletion occurs. Therefore, as a mechanism autophagy
could be theoretically cytoprotective on the one hand, or destructive
on the other, if stress becomes so advanced that cellular elimination is
required. After the initial report of autophagy during HI injury, when
autophagic expression of LC-3-II was found to be more prominent in
older animals than in young rat brain where cell death (both caspase-
dependent and caspase independent) was more pronounced [193],
there has been recent increased interest in the role of autophagic
mechanisms in HI [201]. In focal ischaemia there is increasedformation of autophagosomes and autolysosomes, and elevated
expression of LC-3, cathepsin B, and Beclin-1 [202,203]. In the
ischaemic penumbra approximately 30% of cells show caspase-3
activation and up-regulation of Beclin-1 suggesting that the two
pathways may be occurring in parallel and independently in different
neuronal populations, and that autophagy could have both protective
and destructive outcomes [204]. In neonatal HI, Beclin-1-positive cells
were also TUNEL-positive and were increased in both cortex and
hippocampus. Further, rapamycin in vivo increased expression of
Beclin-1, decreasing both necrosis and injury [205]. Autophagy may
also occur concurrently with necroptosis during transient focal
cerebral ischaemia [21].
4.3. Amyotrophic lateral sclerosis
ALS is characterized by the death of upper MNs in themotor cortex
and of lower MNs in the brainstem and spinal cord [206]. The
aetiology of most cases of ALS is unknown but proposed mechanisms
of neurotoxicity include misfolded protein aggregation, ER stress,
mitochondrial dysfunction, excitotoxicity, oxidative damage from ROS
or reactive nitrogen species (collectively RONS), UPS dysfunction, and
axonal transport defects [207]. Most cases arise sporadically (sporadic
ALS (SALS)) but 2% of all ALS cases are familial (FALS) linked to
mutations in Cu/Zn superoxide dismutase 1 (SOD1). Transgenic
rodents over-expressing mutant human SOD1 develop symptoms and
pathological features that recapitulate human disease and are the
most widely accepted animal model [208,209].
There is substantial evidence that molecular components of
mitochondrial pathways of PCD play a role in neurodegeneration in
both SOD1 rodents and in mutant SOD1 over-expressed in cell culture
(reviewed in [206,210]). The death receptor pathway has also been
implicated in experimental models of ALS via Fas/CD95 receptor
stimulated caspase-8 activation [211] or TNFR1 and p75 neurotrophin
receptor [212,213]. However, in humans the evidence is more
conﬂicting, perhaps reﬂecting the extensive degeneration, scarcity
of MNs and notorious difﬁculty in detecting PCD in post-mortem
tissues [214]. In some studies, morphological features of PCD have
been described in human ALS tissues, including condensed nuclei,
DNA fragmentation and fusiform cells devoid of processes [215,216].
However contradictory ﬁndings have been obtained in other studies,
in which degenerating human MNs did not demonstrate apoptotic
morphology [217–219].
Accumulating evidence suggests that mitochondrial dysfunction is
involved in the pathogenesis of ALS and possible mechanisms include
Ca2+-mediated excitotoxicity, increasing generation of ROS, and
initiation of PCD by various pathways. Morphological and ultrastruc-
tural abnormalities of mitochondria are well documented in human
ALS post-mortem anterior horns and proximal axons [220–222], and
in muscle biopsy tissue [223]. Concomitantly, the activities of
mitochondrial respiratory chain in human SALS tissues are reduced
in complex I [224] and complex IV [225] in the skeletal muscle and in
the spinal cord of SALS patients [226–228], correlating with disease
progression [227]. Oxidative damage [229–231], excessive mitochon-
drial Ca2+ accumulation, and calpain activation (reviewed in [232])
are also features of human ALS MNs. More recently our laboratory
implicated ER stress as an important pathway in neuronal cell death in
human ALS. The full spectrum of ER stress mediators, including UPR
sensors, ER chaperones and apoptotic effectors (CHOP, caspase-3, JNK
kinase, p38 and caspase-4) were upregulated in ALS post-mortem
lumbar spinal cords in comparison to controls [233]. PDI was also
signiﬁcantly upregulated in cerebrospinal ﬂuid from SALS patients
and in the surviving MNs of SALS patient tissues. In these tissues PDI
was widely distributed and associated with intracellular inclusions,
thus linking the UPR and misfolded protein aggregation with neuro-
toxicity in ALS. Consistent with our observations, another study
reported the up-regulation of PDI and phosphorylation of eIF2α in
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chondrial function, proteasome activity, and ER stress was also im-
plicated in sporadic disease [229].
Whilst studies using human tissues are informative, detailed
investigations in experimental models allow pathogenic mechanisms
to be dissected. Morphological abnormalities and dysfunction of mito-
chondria are well documented in cellular and animal models of ALS,
and in mice over-expressingmutant, these irregularities are identiﬁed
prior to the onset of symptoms, thus implying an active role for mito-
chondria in pathogenesis. A portion of mutant SOD1 is mislocalised to
mitochondria, where it forms aberrant aggregates and protein inter-
actions [234–236] that are spinal cord-selective and age-dependent
[237]. Vacuolation derived from degenerating mitochondria is a stri-
king pathological characteristic in transgenic SOD1G93A or SOD1G37R
mice, which increases dramatically at the onset of disease [238]. A
higher level of RONS [239] and impairment of mitochondrial ener-
getics [235] are also observed in SOD1G93A mice, and in cells express-
ing SOD1 mutants in vitro [240]. More recently, the MPT pore was
causally implicated inMN degeneration in SOD1mice [241]. Improper
transport of mitochondria through long MN axons (up to 1 m in
length) could also contribute to neurodegeneration, and disruption of
both fast and slow axonal transport is well documented in ALS
(reviewed in [242] and [243]). Inhibition of anterograde fast axonal
transport of mitochondria was recently detected in MNs of mutant
SOD1 mice, leading to their asymmetric redistribution [244]. Further-
more, mitochondrial dysfunction correlated with impaired mitochon-
drial transport in ALS (reviewed in [243]). This unequal distribution of
mitochondriamay limit their local availability in some cellular regions,
leading to a deﬁcit in energy utilization or Ca2+ buffering capacity,
which may have important consequences due to the particularly low
Ca2+ buffering capacity of MNs compared to other cell types [245].
Recent studies have documented convincingly a role for ER stress
and UPR-induced PCD of MNs in ALS. ER stress also has close
connections with other pathways implicated in ALS, involving triggers
such as excitotoxicity and oxidative stress, and responses including
autophagy and the UPS [121,126,229,246]. Our laboratory demon-
strated that up-regulation of the whole spectrum of UPR mediators
occurs in lumbar spinal cords of SODG93A mice [247], including
caspase-12, CHOP and downstream effectors caspase-9 and caspase-3.
Other reports also describe the up-regulation of UPR proteins
[229,248–250] or dysfunction of ERAD as a trigger for ER stress
[251] in animal and cellular experimental models of ALS. We and
other workers also detected ER stress in pre-symptomatic animals
[152,229,233] and induction of the UPR correlated with the fast
fatiguable MNs that are targeted ﬁrst in disease [152]. Together these
studies imply that ER stress is an active participant in pathogenesis in
ALS. This hypothesis is borne out by studies demonstrating that
modulation of the UPR in SOD1 mice by either administration of ER
stress inhibitor salubrinal [152] or deletion of ER stress PCD effectors,
BIM [252], ASK1 [251] or PUMA [37] has a beneﬁcial effect on either
motor performance or disease onset or both.
The presence of inclusion bodies containing aggregated and
potentially harmful ubiquitinylated proteins is a typical feature in
MNs of both ALS patients and animal models. The UPR chaperone PDI
was found to be physically associated with mutant SOD1 inclusions in
SOD1G93A mice and in cell culture, implying a relationship between
the UPR and intracellular inclusion formation [247]. This link is borne
out by the ﬁnding that pharmacological agents that modulate ER
stress also alter the formation of inclusions [253]. A recent study
demonstrated that mutant SOD1 inclusions are closely associated
with neurotoxicity in ALS. Only cells bearing inclusions underwent
PCD-Type I via the mitochondrial pathway when mutant SOD1 was
expressed [254]. We also demonstrated that ER stress occurs
upstream of the formation of inclusions of mutant SOD1, suggesting
that oligomeric forms of SOD1 trigger the UPR (Atkin, J.D., unpub-
lished data). We also identiﬁed an important role for Bim in linking ERstress to mitochondrial apoptotic signalling (Soo, K.Y. and Nagley, P.,
unpublished data). There is also evidence that dysfunction of the UPS
[255] or autophagy contributes to inclusion formation and MN death
in ALS models [256,257]. These studies include those based on TDP-43
[126], which has recently received much of attention due to its
potential signiﬁcance in sporadic disease (reviewed in [258]).
4.4. Parkinson's disease
Long before genes implicated in familial PD had been identiﬁed,
the vulnerability of dopaminergic (DA) neurones of the substantia
nigra pars compacta (SNc) had been recognised, oxidative stress
documented and the existence noted of proteinaceous inclusions
termed Lewy bodies [259]. Together this evidence was suggestive of
injury mechanisms involving mitochondrial dysfunction, in associa-
tion with inappropriate handling of abnormal proteins [260,261], and
considered to contribute to the predominant sporadic forms of the
disease. Early analyses in post-mortem PD tissue revealed reduced
glutathione and oxidative damage to proteins, lipids and DNA [262] in
association with decreases in mitochondrial complex I activity by 30-
40% [263]. DNA fragmentation reported in autopsied brain tissue may
be downstream of apoptosis-like injury mediated by Bax and caspases
[264]. Autophagosomes have been identiﬁed also in SNc in post-
mortem PD brain [265,266].
The case for mitochondrial dysfunction in PD was greatly strength-
ened by epic work that found MPTP produced PD-like symptoms in
humans [267]. Further a metabolite of MPTP, MPP+, is transported into
DA neurones where it selectively inhibitedmitochondrial respiration at
complex I of the electron transport chain. Subsequent investigations,
using both cellular and animal models conﬁrmed the pathological
mechanism of MPP+. Moreover, rotenone and paraquat also produced
PD-like actions via mitochondrial complex I [268–270]. The function of
complex I is critical to the maintenance of Δψm and, consequently, to
ATP synthesis. Since MPP+ blocks complex I, its action dissipates Δψm,
predisposingmitochondria to MPT [260]. Whether MPP+ and rotenone
induce DA neuronal injury dependent or independent of caspases [271]
may depend on the cellular milieu (especially redox and energetic
status), but recent evidence indicates mitochondria-mediated injury
favouring caspase-independent apoptotic mechanisms involving pref-
erential redistribution of AIF [272,273]. MPP+ also possesses the
capacity to activate autophagy in DA cell lines and neurones [70].
Paraquat can produce caspase-dependent and proteasome-dependent
PCD via ER stress [274]. Finally, we should note that genes causing
familial forms of PD encode mitochondrial proteins such as PTEN-
induced kinase 1 (PINK1) and DJ-1, or are linked to mitochondrial
dysfunction (αSN and Parkin) [261,275–277].
αSN is a constituent of Lewy bodies a hallmark of PD, which is just
one of a wide group of synucleinopathies [278]. The neurobiology of
αSN remains poorly understood - it is localized to various intracellular
components, including synaptic vesicles where its association is
activity-dependent [279]. Only with the detection of a mutant species
of αSN in a familial form of PD [280] was its pathological role
suspected, providing the ﬁrst evidence for a gene causing the disease.
Other forms of PD are associated with the gene encoding αSN and
with variants around the gene. Expression of αSN in cellular systems
has detrimental effects, but its over-expression or gene delivery
produces animal models where loss of SNc DA cells is generally more
modest than in the human disease [276,279]. The mitochondrial
import of mutant αSN depends on ATP and Δψm, and its association
with complex I was recently reported in post-mortem PD tissue
[281,282]. Recent advances in our understanding of differential
involvement of PCD in neuronal injury have led to renewed interest
in whether accumulation of αSN preferentially exposes neurones to
elimination by ER stress and/or autophagy [261]. Mild accumulation
of αSN induces the protective phases of UPR and autophagy (Tinsley,
R.B. and Horne, M.K., personal communication). Oligomeric αSN
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as to the toxic contributions of ﬁbrillary, oligomeric and aggregated
αSN. Effects ofαSN on ER-Golgi trafﬁckingmay underlie ER stress and
Golgi fragmentation [276,279]. In cell lines, mutant αSN induces ER
stress with increased expression of caspase-12 and CHOP, which are
preceded ﬁrst by reduced proteasomal activity and ROS generation,
and second by activation of the intrinsicmitochondrial pathway [283].
Soluble αSN is degraded by CMA whereas its aggregates induce
turnover by autophagy [261].
There is far less evidence linking other more recently discovered
genes tomitochondrial dysfunction and PCD. Although sporadic forms
of PD are much more common than genetic PD, the identiﬁcation of
autosomal dominant and negative genes has allowed unprecedented
insights into pathogenic mechanisms that might contribute the
panoply of clinical symptoms grouped under PD. An extensive range
of studies on various genes implicated in familial forms of PD has
established the importance of the UPS and inappropriate protein
handling as key pathological features of the disease [261,276,279].
Three proteins encoded by such genes are considered here, namely,
Parkin, PINK1 and DJ-1.
Parkin exhibits E3 ubiquitin ligase activity in vitro and catalyses
various types of ubiquitinylation [284] butwhether its ligase activity is
essential for a protective role remains unknown [275,276]. Parkin
appears to have an evolutionary conserved function and the knockout
mouse exhibits reduced mitochondrial respiratory activity promoting
oxidative stress [285]. Recent evidence in cell lines indicates that
Parkin is recruited to dysfunctional mitochondria in an ATP-indepen-
dent, voltage-dependent manner promoting their mitophagy [69].
PINK1 is imported and activated in mitochondria where it is
localized to the IMM, and its deﬁciency results in morphologically
abnormal mitochondria that produce less ATP. There is mitochondrial
fragmentation and reduced OMMP in PINK1-deﬁcient human cell
lines and the phenotype is reduced by expression of Parkin [286],
which might activate autophagy of dysfunctional mitochondria
resulting from loss of PINK1 function. Knockdown of PINK1 produced
mitochondrial fragmentation, oxidative stress, mitophagy and more
general autophagy in cultured cells, whilst its over-expression was
cytoprotective [287]. The interaction of PINK1 and the IMS protein
HtrA2/Omi via the same stress pathway is currently controversial
[288,289]. Nevertheless HtrA2/Omi, a mediator of caspase-dependent
PCD, has been implicated in PD on molecular genetic grounds [290].
DJ-1 is partially localized to mitochondria and appears to possess
activity as an anti-oxidant protein or redox sensor preventing cell
death [291]. DJ-1-null mice possess altered striatal DA function [292]
and are hypersensitive to MPTP [293]. Paraquat produces autophagy
in cell lines with silenced DJ-1 [294].
These three genes affecting mitochondrial function appear to be
part of an ubiquitin E3 ligase complex promoting unfolded protein
degradation. Decreased expression of PINK1 or DJ-1 reduced
ubiquitinylation of Parkin suggesting their cooperativity in an E3
ligase complex is vital to UPS activity and dysfunction pathogenic in
PD [295]. A further link to the UPS may be via mutation of ubiquitin-
C-terminal hydrolase-L1 (UCH-L1), which is associated with familial
PD [276]. Its expression increases αSN apparently via CMA [296].
Aberrant activities of several kinases may contribute to the
pathogenesis of PD, notably through mutations in LRRK2 (leucine-
rich repeat kinase 2, PARK8), which are associated with a
monogenetic form of PD, and cause tau-positive, αSN-negative
inclusions of affected neurones. Mutant LRRK2 affects neuritic
length and branching causing apoptosis [297], and its knockdown
has a gain-of-function effect [261]. LRRK2 may be linked to the Akt/
mTOR pathway, a key regulatory step in autophagy [298]. Akt itself
has various inﬂuences, especially though the Bcl-2 family of
proteins, and inhibition of Akt-mediated signalling by PD toxins
could underlie effects on SNc neurones in post-mortem PD tissue
[299].4.5. Huntington's disease
Unlike ALS and PD, Huntington's disease (HD) is caused by
mutation of a single gene, Huntingtin (Htt) [300], where expansion of
the polyglutamine CAG repeats beyond 40 determines whether the
disease is of juvenile or adult-onset [301]. This dominant gain of
function results in pathological changes, which were initially
considered to involve predominantly the caudate-putamen (corpus
striatum), but have now been identiﬁed to involve degenerative
changes in other brain regions, especially the cortex. Although, the
disease-susceptibility of striatal and cortical neurones remains
unexplained [302,303], the restriction of Htt expression to glutama-
tergic pyramidal neurones in mousemodels of HD fails to produce the
full pathology and motor deﬁcits, implying that multiple processes
involving both cell and non-cell autonomous mechanisms work in
concert [304]. Nevertheless, the striatum undergoes appreciable
shrinkage where its medium-sized spiny GABAergic neurones are a
principal target of neurodegeneration, although whether the direct or
indirect output pathway from the striatum is preferentially affected
remains unresolved [302,303,305].
There is clear evidence from diverse studies employing post-
mortem brain tissue that PCD contributes to the neuropathology of
HD, although its temporal patterns of recruitment and how the Htt
aggregate load inﬂuences the cell death mechanisms need to be fully
delineated. These ﬁndings include striatal neurones displaying
shrinkage of their neuritic tree, alterations of various intracellular
organelles including the ER, increased caspase and calpain activities,
the presence of potentially toxic aggregates and inclusions, an
activated UPS and evidence for autophagosomes [303,305,306].
Striatal cells expressing mutant Htt display increased Ca2+ sensi-
tivity of ΔΨm and are more vulnerable to the complex II inhibitor,
3-nitropropionic acid [307,308]. Reported deﬁcits in mitochondrial
complex II in the striatum of symptomatic HD patients would in
theory generate destructive ROS, which have detrimental effects on
ΔΨm impairing ATP production and ROS-scavenging mechanisms
[302]. Although the relevance of this facilitation of Ca2+-mediated
ΔΨm in immortalized striatal cells has remained unclear, recent
ﬁndings of a large change in ΔΨm downstream of NMDA receptor
activation in mutant Htt versus wild-type striatal neurones [309] are
consistent with older evidence for altered NMDA receptors and
NMDA receptor-mediated excitotoxicity emergent from studies in
autopsy brain tissue from HD patients [310]. Moreover, since the
commonly accepted view is that impairments of mitochondrial
respiratory enzyme activities are likely to be secondary rather than
primary events in disease aetiology [302], these data offer a potential
link in early disease between excitotoxicity and mutant Htt-induced
mitochondrial and energetic defects. Mutant Htt shifts the mitochon-
dria-mediated injury pattern induced by 3-nitropropionic acid away
from PCD-type I to a caspase-independent form of cell death
apparently via altered Ca2+-mediated ΔΨm [311]. Other evidence
supports such involvement of alternative, caspase-independent,
modes of PCD. In HD caudate nucleus, despite evidence for DNA
fragmentation, minor caspase-3 labelling but enhanced expression of
PARP have been described [312]. Our own group undertook the ﬁrst
detailed study in striatal neurones of mitochondria-mediated redistri-
bution of IMS proteins by pathological stressors and these GABAergic
neurones display a remarkable propensity for caspase-independent
injury on the apoptosis-necrosis continuum with prominent calpain,
but variable insult-dependent caspase-3 activation [95].
Mobilisation of intracellular Ca2+ is important for the activation of
death signalling and the ER has primary roles in intracellular Ca2+
storage, and in protein folding and post-translational modiﬁcation.
Thus evidence of Htt targeting the ER and translocation to the nucleus
upon ER stress is suggestive of its involvement in cellular injury in HD
[306]. Additionally, ﬁndings in various cellular models suggest
triggering of the ER stress response by mutant Htt [313–315].
Fig. 3. Neuronal cellular welfare as a function of the balance between homeostatic and
deleterious factors. In healthy functional neurones (A) homeostasis is maintained by
cellular feedback mechanisms. Under conditions of minor stress (B) homeostasis is
disturbed by deleterious factors (represented by spheres at left) such as RONS and
misfolded proteins (MP). These factors have deleterious inﬂuences on energy
production (ATP) and intracellular Ca2+, the latter being elevated in both cytoplasm
and mitochondria by entry via various channels and transporters. Neurones possess
inbuilt capacities to respond to minor stress (spheres at right, upward arrows) by
activation of the UPR (in its initial, pro-survival phase) and CMA. With greater
imbalances (indicated by an increased number of vertical arrows; RONS, ATP, and Ca2+),
deleterious factors overwhelm cellular homeostatic processes (C). The UPR switches to its
destructive mode via induction of apoptotic effector proteins such as CHOP, caspase-12
and JNK. The UPS becomes increasingly dysfunctional as neither it nor CMA can
adequately handle the increased load of MP, leading to formation of intracellular
aggregates of MP. In spite of the autophagic process switching to MA, this load of
misfoldedMP cannot be handled adequately. At this stage there is a strong commitment to
death; at which point mitochondrial membrane potential (ΔΨm) usually declines. Finally,
the neurone is overwhelmed by the total level of stress (D), and the cell advances to PCD
(type-I, type-II or type-III, or combinations thereof, as represented in Fig. 4).
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in mouse where it precedes and persists during the formation of N-
terminal Htt inclusions. Moreover, BiP and CHOP mRNAs were found
to be up-regulated two-fold in the parietal cortex of HD post-mortem
tissue providing the ﬁrst evidence for ER stress associated with the
impact of mutant Htt [316]. Such evidence of early activation of ER
stress cascades, with consequent effects on the UPR, suggests these
events could initiate PCD with recruitment of mitochondria-mediated
redistribution of IMS proteins and downstream activation of destruc-
tive proteases. As a consequence of ER stress and UPR, there appears
to be a further interface of PCD mechanisms in that Htt redistributes
from ER and can shuttle between nucleus and cytoplasm to play a role
in autophagy. Indeed the co-existence of Htt in endosomal-lyosomal
compartments is consistent with older evidence for the presence of
autophagosomes and their role in the handling of protein aggregates
[317] and autophagic cell death [306].
5. Conclusions and perspectives
Extensive evidence from research on both animal and cellular
systems indicates that neurones experience a variety of stresses
relevant to acute or chronic neurodegeneration. The stresses recruit
death pathways that can no longer be simply classiﬁed as either
apoptosis or necrosis. Not only are there various types of PCD but also
cells may show features of different types of PCD due to the multiple
death pathways that can operate in parallel and show considerable
extents of cross-talk, including sharing components of the intrinsic
mitochondrial pathway and recruitment of various proteases. Mito-
chondria are involved in most, if not all, of such multifaceted death
pathways. Moreover, mitochondria may be recruited early such as in
cellular responses leading to apoptotic outcomes or they may have
later engagement such as when ER stress occurs. This review has
emphasised the range of mitochondrial responses, including what is
now recognised as classical apoptotic signalling (PCD-Type I) through
redistribution of cyt c and apoptosome formation, or the signalling
that leads to early AIF and Endo G redistribution as primary players in
programmed necrosis (PCD-Type III). Mitochondria may also show
deﬁcits in energisation and consequent loss of ATP synthetic capacity,
and thus be subject to mitophagy in parallel with other autophagic
events leading to cell death (PCD-Type II).
Overall, these considerations have led us to a general schema
(Fig. 3) to represent the balance (or imbalance) between the forces
that cause stress on the one hand (left side of fulcrum) and
ameliorative or restorative factors on the other (right side of fulcrum).
In neuronal homeostasis these ameliorative forces are in balance with
stress, but as the stresses become more pronounced and the
restorative factors less able to cope, the cells undergo greater degrees
of debilitation until death ensues. The factors detailed Fig. 3 are those
appraised in this review andwhich are especially involved in neuronal
stress and death. We have emphasised here that the death outcomes
are indeed multifaceted and we have thus represented this new
understanding as a Venn diagram (Fig. 4) in which the main
classiﬁcations of PCD are displayed. The death outcome(s) for any
given cell under a particular stress in an acute injury or chronic
disease may fall within the zones indicated in Fig. 4. Central to this
diversity of death patterns is the primary player, the mitochondrion,
plus the two parallel process that are known to have important roles
as discussed above, ER stress and the UPS (see also Fig. 1).
Whilst cellular models enable an incisive dissection of the speciﬁc
molecular details of cell death pathways and their cross-talk, animal
models can provide a closer link to the “authentic” pathobiological
scenario as occurs in clinically presented acute or chronic neurode-
generative disease. This review has integrated such investigative
approaches to encompass acute situations such as oxidative stress or
HI injury, and the chronic neurodegenerative conditions ALS, PD and
HD. The general principles ofmultifaceted neuronal death and the roleof mitochondria have been emphasised in each case. Indeed, it is likely
that many of these general principles may extend, at least in part, to
other pathologies, including AD [318–320].
Animal models directed towards neurodegenerative diseases
include pharmacological models, genetic knockouts affecting partic-
ular genes, and also transgenic animals that over-express speciﬁc
proteins. Each model has its own advantages and disadvantages.
Extrapolation of ﬁndings obtained from studies using animals to the
situation in humans must be approached with caution. Therefore it is
necessary to check all symptomatic features and disease progression
in such animal models. The degree of correlation may thus lead to
Fig. 4. Composite death outcomes in neurones. The death outcomes may show a range
of properties in terms of both biochemical mechanisms and cellular morphologies (see
text and Figs. 1 and 2, herein). The relative emphasis of each type of death process is
dependent upon the neuronal cell type and the stresses undergone. The icons in the
central common zone indicate key players considered in this review, namely,
mitochondria, ER stress and the UPS (icons as in Fig. 1).
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the clinical situations.
Notwithstanding the detailed information obtained to date about
the cell death pathways in individual neuronal model systems, a
further context that requires much deeper analysis is the relationship
between neurones and juxtaposed glial cells in the physiological
milieu. A speciﬁc issue is whether a particular neurodegenerative
disease is cell-autonomous, where neurones form the primary
defective entities in isolation from surrounding cells. Additionally,
there are also functional changes in glial cells, such as astrocytes,
which normally sustain neurones. Such glial perturbations (non-cell-
autonomous) are thought to apply in ALS and several other
neurodegenerative disorders [13,206,321]. Thus, whilst we can
analyse multifaceted death in neurones under various stresses that
replicate a relevant aspect of a particular disease, the full under-
standing of the pathobiological processes requires us to learn much
more about all the cells that such neurones may interact with.
Astrocytes, for example, display very different biological proﬁles
when they become “reactive” and an emergent literature indicates the
normal homeostatic or sustenance relationships, are disrupted
turning them instead into “collaborators in neurotoxicity” [13].
Finally, brief mention can be made of the potential for
development of new therapeutic agents based on understanding of
the processes leading to the multifaceted deaths that neurones may
undergo. Appreciation of the complexity of interactions affecting
mitochondria and the range of downstream outcomes and parallel
factors, as represented in Fig. 1 and Fig. 3, may lead one to conclude
that approaches based on suppression of just one death outcome
(e.g. PCD-Type I, using small molecule caspase inhibitors) may not
work effectively. The death pathways may be shifted under such a
regime of treatment [171]. In order to achieve effective results in
neuroprotection it might be better to address the upstream
signalling processes and the mitochondria themselves. The issues
here are perhaps opposite to those in much of cancer research where
activating death of “rogue” cells is paramount. Neuroprotective
strategies should be addressed to preventing cell death while
preserving optimal neuronal function. Indeed, one can present a
strong case for “polypharmacy” strategies targeting multiple
upstream mechanisms and cellular compartments such as the ERand proteasome. Identiﬁcation of the relevant death pathways and
in particular diseases and learning how to block their initiation
(rather than their execution) will be key to future therapeutic
strategies.
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